Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6118063 | 1.00 | USP2 (0.48) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL4465842 | 1.00 | USP2 (0.48) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL9675619 | 0.89 | USP2 (0.40) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL4361309 | 0.89 | USP2 (0.40) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL4361313 | 0.89 | USP2 (0.40) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL7480571 | 0.86 | — | — | |
| SCHEMBL7480573 | 0.86 | — | — | |
| SCHEMBL7804173 | 0.85 | ALDH1A1 (0.37) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL2167533 | 0.85 | KDM4E (0.37) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL2167535 | 0.85 | KDM4E (0.37) | USP2TSHRALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| EP-4219516-A2 | CHIRAL CONTROL | Wave Life Sciences Ltd. (SG) | 2023-08-02 | — | — | EP | disclosed |
| US-11643657-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-09 | — | — | US | disclosed |
| EP-2872147-B1 | METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES | WAVE LIFE SCIENCES LTD (SG) | 2022-12-21 | — | — | EP | disclosed |
| US-11114693-B2 | Electrolytic solution for nonaqueous electrolytic solution secondary batteries and nonaqueous electrolytic solution secondary battery | CENTRAL GLASS COMPANY, LTD. (JP) | 2021-09-07 | — | — | US | disclosed |
| US-20210130821-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2021-05-06 | — | — | US | disclosed |
| CN-107851847-B | Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same | 中央硝子株式会社 | 2020-12-18 | — | — | CN | disclosed |
| EP-3333962-B1 | ELECTROLYTIC SOLUTION FOR NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERIES AND NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY | CENTRAL GLASS CO LTD (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200212485-A1 | Non-Aqueous Electrolyte Solution and Non-Aqueous Electrolyte Battery in Which Same Is Used | CENTRAL GLASS COMPANY, LIMITED (JP) | 2020-07-02 | — | — | US | disclosed |
| US-10590413-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2020-03-17 | — | — | US | disclosed |
| WO-2009090548-A2 | 3-AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS, S.A. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2008010061-A2 | 3-AZABICYCLO [3.1.0] HEXANE VANILLOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1375496-B1 | N-ARYL-SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | EISAI R&D MAN CO LTD (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-7112593-B2 | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient | EISAI CO., LTD. (JP) | 2006-09-26 | — | — | US | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| US-20040072830-A1 | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1375496-A1 | N-ARYL-SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130821-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | USP2 3936/4885TSHR 3259/4885ALDH1A1 2867/4885 |
| US-20040072830-A1 | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient | COASY, HCCS, SQLE | USP2 3445/4885TSHR 3428/4885ALDH1A1 1799/4885 |
| US-11114693-B2 | Electrolytic solution for nonaqueous electrolytic solution secondary batteries and nonaqueous electrolytic solution secondary battery | ESPL1, TST, PEF1 | USP2 4743/4885TSHR 4303/4885ALDH1A1 1379/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | USP2 3936/4885TSHR 3259/4885ALDH1A1 2867/4885 |
| US-20200212485-A1 | Non-Aqueous Electrolyte Solution and Non-Aqueous Electrolyte Battery in Which Same Is Used | SLC9A1, TST, CA1 | USP2 4694/4885TSHR 4390/4885ALDH1A1 891/4885 |
| US-11643657-B2 | Chiral control | RNGTT, POLI, NSUN3 | USP2 3936/4885TSHR 3259/4885ALDH1A1 2867/4885 |
| US-10590413-B2 | Chiral control | RNGTT, POLI, NSUN3 | USP2 3936/4885TSHR 3259/4885ALDH1A1 2867/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | USP2 1490/4885TSHR 3417/4885ALDH1A1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.